MAYNE PHARMA GROUP LIMITED
ASX:MYXPharmaceuticals, Biotechnology & Life SciencesToday’s holders own 95.1% of what they think they own, once every option and right converts.
Options/rights overhang 5% of shares
As of August 2026, its latest share-count filing, MAYNE PHARMA GROUP LIMITED had 82M ordinary shares, and no new share-issuance filings have been lodged since January 2024. The company raised no capital through any cash placement, rights issue or share purchase plan in the 24-month window. Options and rights on issue could convert into 4M new shares, equal to 5.2% of the current share count, none in the money; no filing on record states an expiry date for these securities. The company has more than 4 quarters of funding at the recent spend rate, and no proposed securities issues are pending.
Quick answers · 3
Why was MYX in a trading halt?
Mayne Pharma Group requested a trading halt on 14 Oct 2026, giving the reason "Pending release of announcement regarding the Supreme Court of New South Wales, Court of Appeal decision on Cosette's appeal". Trading was expected to resume 16 Oct 2026.
How much placement capacity does MYX have left?
About 99% of the 15% placement capacity left, about 1% used in 12 months (estimate). Under ASX Listing Rule 7.1 a company may place up to 15% of its shares in 12 months without shareholder approval.
How many options and rights does MYX have outstanding?
Unexercised options and rights equal 5.2% of Mayne Pharma Group's shares on issue.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 5 filings (Appendix 2AThe form a company lodges to have new securities quoted on the ASX. It restates how many of each class are on issue. quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 7 Oct 2026 | 3H · cancellation | MYX : ORDINARY FULLY PAID | 81.9M | Appendix 3H |
| 8 Sept 2026 | 3G · unquoted | MYX : ORDINARY FULLY PAID | 81.9M | Appendix 3G |
| 8 Sept 2026 | 3H · cancellation | MYX : ORDINARY FULLY PAID | 81.9M | Appendix 3H |
| 28 Aug 2026 | 2A · quoted issue | MYX : ORDINARY FULLY PAID | 81.9M | Appendix 2A |
| 5 Aug 2026 | 3G · unquoted | MYX : ORDINARY FULLY PAID | 81.2M | Appendix 3G |
Securities on issue over time
Ordinary shares and every option and rights class, month by month over two years. The top edge is the fully diluted count.
Capital raises
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 / 7.1ARule 7.1 lets a company issue up to 15% of its shares in 12 months without a shareholder vote. Rule 7.1A adds 10% for smaller companies whose holders approve it. allows 15% of ordinary securities in any 12 months, and every Appendix 3BNotice that a company proposes to issue new securities, such as a placement. The securities are not on issue until a later filing confirms it. states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
No option supply on record carries an exercise price to pay, so no share price switches any of it on. All 4.2M of it converts on something else — a hurdle that may never be met, or terms the filing does not price.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| MYXAN | Performance rights | Condition-triggered | — | — | 4.2M | Filing Meeting |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column. For what expires soon across other listed companies, see the options expiry calendar.
A condition-triggered class has no exercise price and usually no expiry: what it vests on is set by a shareholder resolution, not by the register. Where the company lodged a notice of meeting before the class first appears here, it is linked as “Meeting” — that is where terms of this kind are put to shareholders. It is not confirmation that the document sets this class’s conditions, and no link appears where there is no such filing.
- MYXAAconvertible notes28k7 Oct 2026 Appendix 2A
Director dealings
| Date | Director | Type | Shares | Options | Other | Value | Source |
|---|---|---|---|---|---|---|---|
| 16 Dec 2025 | Shawn Patrick O'Brien | Sell on-market | 326k | — | — | $401k | 3Y notice |
| 28 Feb 2022 | Bruce Robinson | Sell | — | — | — | — | 3Y notice |
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 Oct 2026.